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Abstract
Background: Glutathione S-transferase (GST) enzymes
are critical for detoxifying reactive oxygen species
(ROS) and their products which have been implicated
in the pathology of inflammatory diseases such as
atopic dermatitis (AD).
Methods: We investigated the effects of genetic poly-
morphisms of GST on the risk of AD in preschool age
children. Biomarkers for oxidative stress were also
evaluated with respect to GST genotype.
Results: The GSTP1 Val105 allele was significantly
associated with an increased risk of AD wodds ratio
(OR)s1.62, p-0.05x. The combination of the GSTP1
Val105 allele and the GSTT1 null genotype further
increased this risk by 2.3-fold (p-0.01). No associa-
tion was observed for the GSTM1 null or GSTT1
null genotype alone. In children with AD, blood total
antioxidant capacity was significantly less (p-0.001),
while malondialdehyde was higher (ps0.12). Children
with the GSTP1 Val105 allele had significantly lower
concentrations of erythrocyte glutathione compared
to GSTP1 Ile/Ile homozygotes (ps0.03).
Conclusions: Our study suggests that the GSTP1
Val105 allele is an important determinant of suscep-
tibility to AD in preschool age children and increased
oxidative stress may play a role in the pathogenesis
of AD.
Clin Chem Lab Med 2009;47:1475–81.
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Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin
disease characterized by pruritic and eczematous skin
lesions in distinct locations. The onset of AD usually
occurs in early childhood, with ;80% of cases having
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clinical symptoms by 5 years of age (1). AD is the
most common allergic childhood disease, affecting
up to 20% of children worldwide (2).
While the pathology of AD is very complex and not
fully understood, it is widely accepted that both
genetic and environmental factors contribute to the
development of AD. The genetic contribution seems
to be particularly strong; results from twin studies
show that disease concordance rates are much higher
in monozygotic (72%–86%) compared with dizygotic
twins (21%–23%) (3). In addition, recent studies have
found significant associations between AD and poly-
morphisms in genes such as IL4, IL13, IL4R, CMA1,
and SPINK5 (4). These data suggest that multiple
genetic factors contribute to the development of AD.
Inflammation is a critical feature of AD and is often
associated with increased production of reactive oxy-
gen species (ROS). These can cause oxidative dam-
age to cellular components such as DNA, lipids and
proteins. In skin inflammation associated with AD,
ROS are released during the activation and infiltration
of lymphocytes, monocytes, and eosinophils (5–7). In
addition, markers of oxidative stress have been
shown to be increased in children with AD (8), impli-
cating ROS and their products in the pathology of
AD. Thus, it is possible that genetic factors that affect
the capacity of cells to detoxify ROS and their prod-
ucts are important determinants in the development
of AD.
Glutathione S-transferases (GSTs) belong to a mul-
tigene family of phase II detoxification enzymes and
protect cells against oxidative damage. GST detoxi-
fies ROS and their products by catalyzing conjugation
with reduced glutathione (GSH) prior to excretion
from the body (9). Several genetic polymorphisms
have been identified in GSTP1, GSTM1, and GSTT1
isozymes. A single nucleotide substitution (A–G),
resulting in an Ile to Val change at residue 105, has
been associated with altered heat stability and sub-
strate preference of GSTP1 (10). Similarly, homozy-
gous deletion of the GSTM1 and GSTT1 genes leads
to the absence of the GSTM1 and GSTT1 proteins and
their activity resulting in a null phenotype (11). Pre-
vious studies have reported an association between
GST polymorphisms and an increased risk of inflam-
matory diseases such as asthma (12–16) and rheu-
matoid arthritis (17). A limited number of studies have
examined the association of GST polymorphisms
with risk of AD; the findings have been inconclusive
(18–20). The purpose of this study was to investigate
the relationship of polymorphisms in GSTM1, GSTT1,
and GSTP1 with the risk of AD in preschool age chil-
dren. In addition, biomarkers of oxidative stress were
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analyzed with respect to GST polymorphisms in chil-
dren with AD and healthy children.
Materials and methods
Subjects
To investigate the association between various selected
factors and childhood AD, we conducted a cross-sectional,
population-based study using a convenience sample of chil-
dren, 2–6 years old, from 18 preschools located in two met-
ropolitan cities (Seoul and Incheon) of Korea. Of the 1571
children who participated in the cross-sectional study, 765
were recruited for the genetic case-control study. Of these,
we selected AD cases and controls based on responses to
questions in the Korean version of the International Study of
Asthma and Allergies in Childhood (ISAAC) questionnaire
(21). AD was considered to be present if the children’s par-
ents replied positively to the following questions: ‘‘Has your
child ever had an itchy rash (also called atopic dermatitis),
which was coming and going for at least 6 months?’’ and,
‘‘Has your child had this itchy rash at any time in the last
12 months?’’. The children whose parents provided negative
responses to both questions and who had not taken any
medication due to AD were assigned as control subjects. All
of the study subjects were Korean. Information concerning
basic demography and history of family atopic diseases
was also collected from the questionnaire. The severity of
AD was evaluated by a pediatrician using the Scoring Atopic
Dermatitis (SCORAD) index. All participants providedwritten
informed consent for study participation. The study protocol
was approved by the Ethics Committee of the College of
Human Ecology at Kyung Hee University.
Genotyping
Genomic DNA was extracted from buffy coats using the
AxyPrep Blood Genomic DNA miniprep kit (Axygen biosci-
ences, Union City, CA, USA). Polymorphism in GSTP1
Ile105Val was identified using the PCR-restriction fragment
length polymorphism (RFLP) method, as described previous-
ly (22). Briefly, 50 ng genomic of DNA was used as template
in a PCR reaction with the HotStar DNA polymerase kit
(Qiagen, Valencia, CA, USA) and an MJ mini gradient ther-
mal cycler (Bio-Rad, Hercules, CA, USA). PCR conditions
were initial denaturation at 958C for 5 min, followed by 35
cycles of 558C for 30 s, 728C for 30 s, and 958C for 30 s, and
a final extension at 728C for 5 min. PCR products (176 bp)
were digested with 2.5 units Alw26I (New England Biolabs,
Ipswich, MA, USA), separated on a 3.5% agarose gel and
stained with ethidium bromide. Bands were detected using
the Gel Doc XR system (Bio-Rad, USA). The presence of the
GSTP1 Val105 allele was identified by detection of cleaved
PCR products (91 bp and 85 bp) following digestion. A mul-
tiplex PCR method was used to detect GSTT1 and GSTM1
polymorphisms, with the b-globin gene used as internal
standard. Briefly, GSTM1, GSTT1, and b-globin genes were
amplified simultaneously amplified by PCR using mixed
primers for each gene, as described by Wilson et al. (23).
PCR conditions were initial denaturation at 948C for 3 min,
followed by 27 cycles of 948C for 30 s, 628C for 30 s, and
728C for 45 s, and a final extension step of 10 min at 728C.
Following amplification, the PCR products were analyzed on
a 2% agarose gel and stained with ethidium bromide. The
presence or absence of the GSTT1 (480 bp) and GSTM1
(215 bp) genes was determined in the presence of the control
b-globin gene (268 bp).
Serum total antioxidant capacity (TAC)
Serum TAC was measured using a commercially available
kit (Antioxidant Assay kit, Cayman chemical, Ann Arbor, MI,
USA) following the manufacturer’s instructions. The assay is
based on the ability of antioxidants to inhibit the oxidation
of ABTS w2,29-Azino-di-(3-ethylbenzthiazoline sulfonate)x to
ABTS•q by metmyoglobin (24). The amount of ABTS•q pro-
duced was monitored spectrophotometrically at 750 nm.
TAC of serum was compared with that of Trolox, a water-
soluble tocopherol analogue, and quantified as the mM
Trolox equivalent.
Erythrocyte total GSH
Erythrocyte total GSH concentrations were determined as
described by Rahman et al. (25). Briefly, erythrocyte pellets
were resuspended in four volumes 5% meta-phosphoric acid
(MPA) to prevent oxidation of GSH. Following centrifugation
at 3000=g at 48C for 10 min, the clear supernatants were
collected and mixed with Ellman’s reagent wDTNB (5,59-
dithio-bis(2-nitrobenzoic acid))x and GSH reductase in the
dark. After incubation at room temperature for 30 s, the reac-
tions were initiated by the addition of b-NADPH. The rate of
formation of TNB at 412 nm during the first 2 min was pro-
portional to total GSH concentration. Values for total GSH
were calculated from a standard curve and expressed as
mmol/g Hb.
Plasma malondialdehyde (MDA)
Plasma MDA was measured using a commercially available
kit (Bioxytech MDA-586, Oxis International, Inc, Foster
City, CA, USA). This colorimetric assay uses N-methyl-2-phe-
nylindole (NMPI) as chromogen. It reacts specifically with
MDA, but not with other lipid peroxidation products such
as 4-hydroxyalkenals. Plasma MDA concentrations were
derived by calculating the third derivative spectrum of the
absorption spectrum (400–700 nm) for each sample, accord-
ing to the manufacturer’s recommendations. Third derivative
spectroscopy helps eliminate or reduce the effects of base-
line drift and interference from other biologic compounds
in the sample.
Statistical analyses
All data were analyzed using SAS for Windows 9.1 (SAS
Institute Inc., Cary, NC, USA) and SigmaPlot 10.0 (Systat
Software Inc., San Jose, CA, USA). To test differences
between children with AD and healthy controls, Student’s t-
test or the x2-test was used, as appropriate. For the associ-
ation between GST genotypes and risk of AD, logistic
regression analysis was performed to calculate the odds
ratio (OR) and 95% confidence intervals (CI), after controlling
for gender and age.
Results
Associations between GST polymorphisms and AD
susceptibility were studied in 124 unrelated children
with AD and 260 healthy children. Table 1 summariz-
es the characteristics of study participants. Compared
to controls, the group with AD had significantly higher
concentrations of serum total IgE and blood eosino-
phil counts, typical characteristics of AD. In addition,
the proportion of children with a parental history of
allergic diseases was significantly higher among chil-
dren with AD compared with controls. Age, body
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Table 1 Characteristics of the study populationa.
Characteristics ADb patients Controls p-Valuec
(ns124) (ns260)
Age, years 5.3"1.8 5.2"1.5 0.58
Boy, % 54.0 49.2 0.38
BMI, kg/m2 15.6"1.6 15.3"1.7 0.19
Total IgE, U/mL 395.7"737.0 205.0"341.0 0.01
Eosinophil count, /mL 342.2"210.8 290.3"190.4 0.02
Parental history of allergic
diseasesd, %
Both parents 17.7 11.2
Father or mother 31.5 25.0 0.04
None 50.8 63.8
aValues are mean"SD or %; bAD, atopic dermatitis. cdifferences between AD patients and controls were tested by x2 or
Student t-test; dallergic rhinitis, asthma or atopic dermatitis.
Table 2 Distribution of GST genotypes among patients with atopic dermatitis (AD) and controls.
Genotype AD patients Controls OR (95% CI)a p-Value
GSTM1
Present 52 (41.9)b 113 (43.5) 1 ref.
Null 72 (58.1) 147 (56.5) 1.042 (0.674–1.610) 0.85
GSTT1
Present 55 (44.4) 129 (49.6) 1 ref.
Null 69 (55.6) 131 (50.4) 1.225 (0.795–1.885) 0.36
GSTP1
Ile/Ile 77 (62.1) 189 (72.7) 1 ref.
Ile/Val or Val/Val 47 (37.9) 71 (27.3) 1.624 (1.029–2.564) 0.04
aOR (odds ratio) and 95% CI were obtained from logistic regression after adjustment for gender and age; bvalues are numbers
(%).
mass index (BMI), and the proportion of males were
not different between the two groups. The severity of
AD as evaluated by the SCORAD index showed that
most children with AD (80%) in the study suffered
from mild disease (data not shown).
Table 2 summarizes the distribution of GSTM1,
GSTT1, and GSTP1 genotypes among children with
AD and controls. In children with AD, the frequencies
of GSTM1 null and GSTT1 null were 58.1% and 55.6%,
respectively. Similarly, more than half of the controls
had null genotypes for GSTM1 and GSTT1, 56.5%
and 50.4%, respectively. Overall, no significant asso-
ciation was found between GSTM1 or GSTT1 null
genotypes and the risk of AD in children. In contrast,
the distribution of the GSTP1 Ile105Val allele was sig-
nificantly different between children with AD and con-
trols. Carriers of the GSTP1 Val105 allele (Ile/Val or
Val/Val) were more frequent among children with AD
compared with controls (37.9% and 27.3%, respec-
tively). Using logistic regression analyses with adjust-
ments for gender and age, children with the GSTP1
Val105 allele had a 1.6-fold increased risk of devel-
oping AD compared to GSTP1 Ile/Ile homozygotes
(95% CI 1.03–2.56) (Table 2). However, this associa-
tion was not statistically significant after Bonferroni
correction for multiple testing. The distribution of
GSTP1 Ile/Ile, Ile/Val, and Val/Val genotypes in con-
trols was 72.7%, 25%, and 2.3%, respectively. The fre-
quency of the Val105 allele was 14.8%.
We also investigated the risk of AD associated with
combinations of two GST genotypes. The combina-
tion of the GSTP1 Val105 allele and GSTT1 null geno-
type increased the AD risk by up to 2.3-fold (95% CI
1.19–4.41) compared to GSTP Ile/Ile homozygotes
and children with GSTT1 genotypes (Table 3). How-
ever, the significance of the association was lost after
Bonferroni correction. The combination of the GSTP1
Val105 allele and the GSTM1 null also appeared to
increase the risk of AD (ORs1.73, 95% CI 0.93–3.21),
although this increase was not statistically significant
(ps0.09). There was no significant increase in AD risk
with respect to GSTM1 and GSTT1 genotypes.
To investigate if the degree of oxidative stress was
associated with AD, we compared blood concentra-
tions of GSH, TAC, and MDA between children with
AD and controls (Figure 1). Mean serum TAC was sig-
nificantly lower in children with AD (1.70 mM trolox
eq.) compared with controls (1.43 mM trolox eq.)
(p-0.001). However, mean plasma concentrations of
MDA were higher, although not significantly, in chil-
dren with AD compared with controls (686.9 nM vs.
593 nM, respectively, ps0.12) (Figure 1).
To further explore the mechanisms that could
explain the association of the GSTP1 polymorphism
with increased risk of developing AD we analyzed
the above biomarkers with respect to the GSTP1
Ile105Val genotype. GSTP1 Ile/Ile homozygotes had
significantly higher concentrations of GSH compared
with Val105 allele carriers (10.8 mmol/g Hb vs.
10.1 mmol/g Hb, respectively, ps0.03) (Table 4).
When we stratified the subjects into two groups (chil-
dren with AD and controls), the association of the
GSTP1 genotype with erythrocyte GSH concentra-
tions in each group was consistent with data derived
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Table 3 Distribution of combined GST genotypes among patients with atopic dermatitis (AD) and controls.
Genotype AD patients Controls OR (95% CI)a p-Value
GSTM1 and GSTT1
Both present 22 (17.7)b 56 (21.5) 1 ref.
Either null 63 (50.8) 130 (50.0) 1.254 (0.702–2.238) 0.44
Both null 39 (31.5) 74 (28.5) 1.309 (0.697–2.459) 0.40
GSTM1 and GSTP1
Present and Ile/Ile 35 (28.2) 82 (31.5) 1 ref.
Present and Ile/Val or Val/Val 17 (13.7) 31 (11.9) 1.270 (0.622–2.593) 0.51
Null and Ile/Ile 42 (33.9) 107 (41.2) 0.894 (0.523–1.529) 0.68
Null and Ile/Val or Val/Val 30 (24.2) 40 (15.4) 1.725 (0.928–3.208) 0.09
GSTT1 and GSTP1
Present and Ile/Ile 35 (28.2) 87 (33.5) 1 ref.
Present and Ile/Val or Val/Val 20 (16.1) 42 (16.1) 1.175 (0.605–2.283) 0.63
Null and Ile/Ile 42 (33.9) 102 (39.2) 1.007 (0.590–1.720) 0.98
Null and Ile/Val or Val/Val 27 (21.8) 29 (11.2) 2.286 (1.186–4.406) 0.01
aOR and 95% CI were obtained from logistic regression after adjustment for gender and age; bvalues are numbers (%).
Figure 1 Blood GSH (A), TAC (B), and MDA (C) in patients with AD and controls.
Data are expressed as median and interquartile ranges. Dashed line («) shows means. p-Values are obtained from Student’s
t-test. GSH, glutathione; TAC, total antioxidant capacity; MDA, malondialdehyde; AD, atopic dermatitis.
Table 4 Blood levels of glutathione (GSH), total antioxidant capacity (TAC), and malondialdehyde (MDA) with respect to
GSTP1 genotype.
GSH, p-Valuea TAC, mM p-Value MDA, nM p-Value
mmol/g Hb trolox eq.
All subjects
GSTP1 Ile/Ile 10.8"0.18b
0.03
1.69"0.02
0.14
611.1"32.2
0.47GSTP1 Ile/Val or Val/Val 10.1"0.23 1.62"0.04 655.6"53.9
AD patients
GSTP1 Ile/Ile 10.5"0.30
0.33
1.49"0.05
0.66
689.2"64.2
0.95GSTP1 Ile/Val or Val/Val 10.0"0.33 1.46"0.05 682.6"98.0
Controls
GSTP1 Ile/Ile 10.9"0.23
0.12
1.75"0.03
0.72
577.0"36.4
0.38GSTP1 Ile/Val or Val/Val 10.2"0.33 1.73"0.05 639.4"64.4
aDifferences between GSTP1 Ile/Ile vs. Ile/Val or Val/Val were tested by Student’s t-test; bvalues are mean"SE.
from all subjects, but this was not statistically signif-
icant (Table 4). No significant differences were found
in TAC or MDA with respect to GSTP1 genotype in
children with AD or healthy controls.
Discussion
GST enzymes are critical for the detoxification of ROS
and their products, which have been implicated in the
pathology of inflammatory diseases such as AD. We
reasoned that genetic polymorphisms of GST
enzymes, which alter cellular protection against oxi-
dative damage, may contribute to the risk of devel-
opment of AD. We examined the association of
GSTP1, GSTM1, and GSTT1 gene polymorphisms
with the risk of AD in preschool age children. The
Val105 allele of GSTP1 was significantly associated
with a higher risk of AD. In addition, children with a
particular combination of variant genotypes (GSTP1
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Val105 and GSTT1 null) had an even greater risk (2.3-
fold increase) of AD, compared to children with
GSTP1 Ile/Ile and GSTT1 present genotypes.
GST gene polymorphisms have been associated
with the risk of various skin diseases. For example,
the GSTP1 Val105 allele has been shown to increase
the incidence of arsenic-related skin lesions (26, 27).
This is consistent with our observations that GSTP1
Val105 allele carriers had an increased risk of devel-
oping AD. However, many reports have shown that
the Val105 allele is associated with a decreased risk
of allergic asthma (12, 13), although some studies
reported that the Val105 allele actually increased the
risk of asthma (14, 16). The GSTP1 Ile105Val poly-
morphism was not significantly associated with aspi-
rin-intolerant asthma in Koreans (28). There are
several possible explanations for the discrepancies
between these studies and our findings. First, the
pathogenesis of asthma and AD may be quite differ-
ent. Asthma involves changes in lung function while
AD is a type of skin disease. Thus, comparison of data
from asthma patients with AD may not be appropri-
ate. Second, the frequencies of the Val105 allele in
Asians are much lower than those of other ethnicities,
which may explain the conflicting findings. For exam-
ple, the Val105 allele decreased the risk of asthma in
Northern Europeans for which the Val allele frequen-
cy is 47.7% (12), whereas the Val105 allele increased
the risk of asthma in the Japanese population for
which the Val allele frequency is 13.4% (14). Studies
in Taiwanese individuals (Val allele frequen-
cys25.3%) (15) have shown that the Ile105 homozy-
gosity was related to an increased risk only in areas
with high air pollution, and no association was found
in areas with low air pollution. These data suggest
that the role of GSTP Ile105Val polymorphisms in the
risk of AD could differ depending on ethnicity. The
frequency of the Val105 allele in our study was 14.8%,
which is very close to that of the Japanese popula-
tion. Finally, other factors such as the subjects
age and environmental factors may also cause
differences.
Unlike the GSTP1 Ile105Val polymorphism, neither
GSTM1 nor GSTT1 present/null polymorphisms alone
had a significant effect on risk of AD. In contrast, we
found that carriers of two variant genotypes (GSTP1
Val105 and GSTT1 null) were at higher risk of AD
than carriers of a single variant GSTP1 or GSTT1 gen-
otype, or carriers of no variant genotypes. Also, the
combined effect of the GSTP1 and GSTM1 variant
genotypes on the risk of AD tended to be higher than
the effect of GSTP1 or GSTM1 variants alone. Similar
to our findings, several studies have indicated that the
influences of GST genotypes on disease risk become
more significant with an increase in the number of
GST variant alleles (29–31). This is likely due to GST
enzymes having similar substrate specificities. While
the absence or defect of a single GST enzyme has
negligible effect on the risk of disease, possibly due
to compensation by other GSTs, defects in multiple
GST enzymes may contribute to significant alterations
in cellular protection against oxidative stress and
increase susceptibility to disease.
Earlier studies have reported that oxidative stress
is associated with the development and severity of
AD. Urine concentrations of 8-hydroxy-29-deoxygua-
nosine (8-OHdG, a marker of oxidative DNA damage)
are significantly higher in children with AD compared
with healthy controls (8). Also, urinary acrolein-lysine
adducts (markers of lipid peroxidation) are signifi-
cantly higher in children with AD (32). Our data
showed that TAC was significantly decreased, but
plasma MDA (products of lipid peroxidation) tended
to be increased in children with AD compared to
healthy controls. This supports the association of oxi-
dative stress and altered antioxidant status with
development of AD. The relatively small difference
in plasma MDA and erythrocyte GSH between the
two groups may be due to the fact that most of the
children with AD that participated in our study had a
mild case of the disease. Niwa et al. (33) have shown
that the concentrations of carbonyl moieties (markers
of oxidative protein damage) are increased in skin
biopsies from patients with AD, and are directly cor-
related with disease severity.
We found that GSTP1 Val105 allele carriers had
significantly lower GSH concentrations compared to
GSTP1 Ile/Ile homozygotes. Although the difference in
GSH concentrations between genotypes is relatively
small and may not be clinically significant, this obser-
vation suggests a potential mechanism for how the
GSTP1 Ile105Val polymorphism increases the risk of
AD. Since GSH is an important component that acts
to scavenge ROS and regenerate other antioxidants,
GSH depletion may represent increased oxidative
stress in GSTP1 Val105 allele carriers. Similar to our
findings, Ercan et al. (34) reported that asthma
patients with homozygous GSTP1 Val105 genotypes
have lower GSH concentrations compared to patients
with other genotypes. The Ile to Val substitution at
position 105 results in steric restriction of the putative
binding site (H-site) due to shifts in the side chains
of several amino acids. This steric hinderance may
alter the substrate specificity and catalytic activity of
GSTP1. In vitro studies have shown that the Val105
variant is more active with diol epoxides of polycyclic
aromatic hydrocarbons (35), but less active than the
Ile105 enzyme with various other substrates, includ-
ing 1-chloro-2,4-dinitrobenzene (36). Further, the ther-
mal stability of the Val105 enzyme is reported to be
significantly lower than that of the Ile105 enzyme (37).
More importantly, erythrocytes from individuals with
the Val105 allele displayed significantly decreased
GST activity compared with that seen in Ile/Ile homo-
zygotes (38). Together, these characteristics may be
responsible for the increased oxidative stress of
GSTP1 Val105 carriers and for the increased suscep-
tibility to AD.
It is interesting to note that serum TAC was much
lower in children with AD compared with healthy con-
trols. However, no significant differences were found
with respect to GSTP1 genotype. This suggests that
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low TAC could be an independent risk factor for AD,
in addition to GSTP1 genotype. Serum TAC measure-
ments represent the combined activities of all anti-
oxidants present in serum, including dietary
antioxidant vitamins such as ascorbic acid, a-tocoph-
erol, and b-carotene (24). The imbalance of ROS pro-
duction and antioxidants can lead to increased
oxidative stress. Thus, it is possible that in addition
to increased ROS production, low TAC in children
with AD may be due to low intake of dietary antioxi-
dants, implicating dietary antioxidant intake with AD
risk. Several previous studies have reported the ben-
eficial association of dietary antioxidant vitamins with
the risk of atopic diseases (39–41). For example, a
higher concentration of vitamin C in breast milk is
associated with a reduced risk of AD in infants
(ORs0.30, 95% CI 0.09–0.94) (42). Further studies to
identify potential interactions between dietary anti-
oxidant intake and GSTP1 genotype in the risk of AD
are needed.
In conclusion, our results suggest that the GSTP1
Val105 allele is an important determinant for suscep-
tibility to AD in preschool age children. These findings
suggest a role for increased oxidative stress and
altered antioxidant status in the pathogenesis of the
disease. This study is limited by the small number of
subjects and the associations of the GST polymor-
phisms with AD risk become suggestive after Bonfer-
roni correction. Further studies with larger sample
sizes are needed to confirm and substantiate the pres-
ent findings.
Conflict of interest statement
Authors report no conflict of interest.
Acknowledgements
The present study was supported by grant No. R01-2006-000-
10887-0 from the Basic Research Program of the Korea Sci-
ence & Engineering Foundation.
References
1. Levy RM, Gelfand JM, Yan AC. The epidemiology of ato-
pic dermatitis. Clin Dermatol 2003;21:109–15.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:
151–60.
3. Schultz Larsen F. Atopic dermatitis: a genetic-epidemio-
logic study in a population-based twin sample. J Am Acad
Dermatol 1993;28:719–23.
4. Chien YH, Hwu WL, Chiang BL. The genetics of atopic der-
matitis. Clin Rev Allerg Immu 2007;33:178–90.
5. Kapp A, Zeck-Kapp G, Czech W, Schopf E. The chemokine
RANTES is more than a chemoattractant: characterization
of its effect on human eosinophil oxidative metabolism
and morphology in comparison with IL-5 and GM-CSF. J
Invest Dermatol 1994;102:906–14.
6. Polla BS, Ezekowitz RA, Leung DY. Monocytes from
patients with atopic dermatitis are primed for superoxide
production. J Allergy Clin Immun 1992;89:545–51.
7. Portugal M, Barak V, Ginsburg I, Kohen R. Interplay
among oxidants, antioxidants, and cytokines in skin dis-
orders: present status and future considerations. Biomed
Pharmacother 2007;61:412–22.
8. Omata N, Tsukahara H, Ito S, Ohshima Y, Yasutomi M,
Yamada A, et al. Increased oxidative stress in childhood
atopic dermatitis. Life Sci 2001;69:223–8.
9. Hayes JD, Strange RC. Potential contribution of the glu-
tathione S-transferase supergene family to resistance to
oxidative stress. Free Radical Res 1995;22:193–207.
10. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini
J. Molecular cloning, characterization, and expression in
Escherichia coli of full-length cDNAs of three human glu-
tathione S-transferase Pi gene variants. Evidence for dif-
ferential catalytic activity of the encoded proteins. J Biol
Chem 1997;272:10004–12.
11. Bolt HM, Thier R. Relevance of the deletion polymor-
phisms of the glutathione S-transferases GSTT1 and
GSTM1 in pharmacology and toxicology. Curr Drug
Metab 2006;7:613–28.
12. Fryer AA, Bianco A, Hepple M, Jones PW, Strange RC,
Spiteri MA. Polymorphism at the glutathione S-transfer-
ase GSTP1 locus. A new marker for bronchial hyperre-
sponsiveness and asthma. Am J Resp Crit Care 2000;
161:1437–42.
13. Hemmingsen A, Fryer AA, Hepple M, Strange RC, Spiteri
MA. Simultaneous identification of GSTP1 Ile105™
Val105 and Ala114™Val114 substitutions using an
amplification refractory mutation system polymerase
chain reaction assay: studies in patients with asthma.
Respir Res 2001;2:255–60.
14. Kamada F, Mashimo Y, Inoue H, Shao C, Hirota T, Doi
S, et al. The GSTP1 gene is a susceptibility gene for
childhood asthma and the GSTM1 gene is a modifier of
the GSTP1 gene. Int Arch Allergy Imm 2007;144:275–86.
15. Lee YL, Lin YC, Lee YC, Wang JY, Hsiue TR, Guo YL.
Glutathione S-transferase P1 gene polymorphism and
air pollution as interactive risk factors for childhood asth-
ma. Clin Exp Allergy 2004;34:1707–13.
16. Tamer L, Calikoglu M, Ates NA, Yildirim H, Ercan B, Sari-
tas E, et al. Glutathione-S-transferase gene polymor-
phisms (GSTT1, GSTM1, GSTP1) as increased risk
factors for asthma. Respirology 2004;9:493–8.
17. Morinobu S, Morinobu A, Kanagawa S, Hayashi N, Nishi-
mura K, Kumagai S. Glutathione S-transferase gene
polymorphisms in Japanese patients with rheumatoid
arthritis. Clin Exp Rheumatol 2006;24:268–73.
18. Nickel R, Haider A, Sengler C, Lau S, Niggemann B,
Deichmann KA, et al. Association study of glutathione S-
transferase P1 (GSTP1) with asthma and bronchial
hyper-responsiveness in two German pediatric popula-
tions. Pediatr Allergy Immu 2005;16:539–41.
19. Safronova OG, Vavilin VA, Lyapunova AA, Makarova SI,
Lyakhovich VV, Kaznacheeva LF, et al. Relationship
between glutathione S-transferase P1 polymorphism
and bronchial asthma and atopic dermatitis. B Exp Biol
Medq 2003;136:73–5.
20. Vavilin VA, Safronova OG, Lyapunova AA, Lyakhovich
VV, Kaznacheeva LF, Manankin NA, et al. Interaction of
GSTM1, GSTT1, and GSTP1 genotypes in determination
of predisposition to atopic dermatitis. B Exp Biol Medq
2003;136:388–91.
21. Oh JW, Pyun BY, Choung JT, Ahn KM, Kim CH, Song
SW, et al. Epidemiological change of atopic dermatitis
and food allergy in school-aged children in Korea
between 1995 and 2000. J Korean Med Sci 2004;19:
716–23.
22. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf
CR. Identification of genetic polymorphisms at the glu-
tathione S-transferase Pi locus and association with sus-
Chung et al.: Association of GST polymorphisms with atopic dermatitis 1481
Article in press - uncorrected proof
ceptibility to bladder, testicular and prostate cancer.
Carcinogenesis 1997;18:641–4.
23. Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-
transferase M1 null genotype is associated with a
decreased risk of myocardial infarction. FASEB J 2000;
14:791–6.
24. Rice-Evans C, Miller NJ. Total antioxidant status in plas-
ma and body fluids. Method Enzymol 1994;234:279–93.
25. Rahman I, Kode A, Biswas SK. Assay for quantitative
determination of glutathione and glutathione disulfide
levels using enzymatic recycling method. Nat Protoc
2006;1:3159–65.
26. Lin GF, Du H, Chen JG, Lu HC, Guo WC, Meng H, et al.
Arsenic-related skin lesions and glutathione S-transfer-
ase P1 A1578G (Ile105Val) polymorphism in two ethnic
clans exposed to indoor combustion of high arsenic coal
in one village. Pharmacogenet Genomics 2006;16:863–
71.
27. McCarty KM, Ryan L, Houseman EA, Williams PL, Miller
DP, Quamruzzaman Q, et al. A case-control study of GST
polymorphisms and arsenic related skin lesions. Environ
Health 2007;6:5.
28. Oh JM, Kim SH, Suh CH, Nahm DH, Park HS, Lee YM,
et al. Lack of association of glutathione S-transferase P1
Ile105Val polymorphism with aspirin-intolerant asthma.
Korean J Intern Med 2005;20:232–6.
29. Oniki K, Hori M, Takata K, Yokoyama T, Mihara S, Maru-
bayashi T, et al. Association between glutathione S-
transferase A1, M1 and T1 polymorphisms and hyper-
tension. Pharmacogenet Genomics 2008;18:275–7.
30. Sorensen M, Raaschou-Nielsen O, Brasch-Andersen C,
Tjonneland A, Overvad K, Autrup H. Interactions
between GSTM1, GSTT1 and GSTP1 polymorphisms
and smoking and intake of fruit and vegetables in rela-
tion to lung cancer. Lung Cancer 2007;55:137–44.
31. Hori M, Oniki K, Nakagawa T, Takata K, Mihara S, Maru-
bayashi T, et al. Association between combinations of
glutathione-S-transferase M1, T1 and P1 genotypes and
non-alcoholic fatty liver disease. Liver Int 2009;29:164–8.
32. Tsukahara H, Shibata R, Ohshima Y, Todoroki Y, Sato S,
Ohta N, et al. Oxidative stress and altered antioxidant
defenses in children with acute exacerbation of atopic
dermatitis. Life Sci 2003;72:2509–16.
33. Niwa Y, Sumi H, Kawahira K, Terashima T, Nakamura T,
Akamatsu H. Protein oxidative damage in the stratum
corneum: evidence for a link between environmental
oxidants and the changing prevalence and nature of ato-
pic dermatitis in Japan. Br J Dermatol 2003;149:248–54.
34. Ercan H, Birben E, Dizdar EA, Keskin O, Karaaslan C,
Soyer OU, et al. Oxidative stress and genetic and epi-
demiologic determinants of oxidant injury in childhood
asthma. J Allergy Clin Immun 2006;118:1097–104.
35. Hu X, Herzog C, Zimniak P, Singh SV. Differential pro-
tection against benzowaxpyrene-7,8-dihydrodiol-9,10-
epoxide-induced DNA damage in HepG2 cells stably
transfected with allelic variants of pi class human glu-
tathione S-transferase. Cancer Res 1999;59:2358–62.
36. Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff
BW, Hildebrandt MA, et al. Glutathione s-transferase p1:
gene sequence variation and functional genomic stud-
ies. Cancer Res 2008;68:4791–801.
37. Johansson AS, Stenberg G, Widersten M, Mannervik B.
Structure-activity relationships and thermal stability of
human glutathione transferase P1-1 governed by the H-
site residue 105. J Mol Biol 1998;278:687–98.
38. Zhong SL, Zhou SF, Chen X, Chan SY, Chan E, Ng KY,
et al. Relationship between genotype and enzyme activ-
ity of glutathione S-transferases M1 and P1 in Chinese.
Eur J Pharm Sci 2006;28:77–85.
39. Devereux G, Seaton A. Diet as a risk factor for atopy and
asthma. J Allergy Clin Immun 2005;115:1109–17.
40. Harik-Khan RI, Muller DC, Wise RA. Serum vitamin levels
and the risk of asthma in children. Am J Epidemiol
2004;159:351–7.
41. Martindale S, McNeill G, Devereux G, Campbell D, Rus-
sell G, Seaton A. Antioxidant intake in pregnancy in rela-
tion to wheeze and eczema in the first two years of life.
Am J Resp Crit Care 2005;171:121–8.
42. Hoppu U, Rinne M, Salo-Vaananen P, Lampi AM, Piiro-
nen V, Isolauri E. Vitamin C in breast milk may reduce
the risk of atopy in the infant. Eur J Clin Nutr 2005;59:
123–8.
